DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert Frederix et al.|The Lancet Oncology|2018Cited by 419
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trialVivianne C. G. Tjan‐Heijnen, R. Vree, Irene E.G. van Hellemond et al.|The Lancet Oncology|2017Cited by 158